Quarterly Report · 10-Q
Processa Pharmaceuticals, Inc. PCSA NASDAQ EQUITY Current
Add to THEMA watchlist → Follow this company’s filings → Quarterly Report Filed Nov 13, 2026 Accepted Nov 13, 2026, 5:10 PM EST CIK 1533743 Accession 0001493152-26-051827
Company context We are a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (“NGC”) small molecules, two of which are in, or have completed, Phase 2 trials, and one is in pre-clinical development.
Current securities Historical securities (1) Registered securities in this filing Processa Pharmaceuticals, Inc. · 10-Q · Filed 2026-11-13
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common Stock, $0.0001 par value per share
Symbol PCSA
Exchange NASDAQ
Classification COMMON Filing context Context: From2026-01-01to2026-09-30
Dimensions: Not supplied
Accession 000149315226051827 · 1 registered-security cover member
Read the exact SEC filing ↗
As-filed source Primary evidence